Astra Zeneca Admits In Court That Which It Must Have KNOWN Before Even Developing Its Gene-Based 'Vaccine'

Says the Telegraph:

Lawyers argue the vaccine produced a side effect which has had a devastating effect on a small number of families.

The first case was lodged last year by Jamie Scott, a father of two, who was left with a permanent brain injury after developing a blood clot and a bleed on the brain that has prevented him from working after he received the vaccine in April 2021. The hospital called his wife three times to tell her that her husband was going to die.

AstraZeneca is contesting the claims but has accepted, in a legal document submitted to the High Court in February, that its Covid vaccine “can, in very rare cases, cause TTS”.

TTS – which stands for Thrombosis with Thrombocytopenia Syndrome – causes people to have blood clots and a low blood platelet count.

Fifty-one cases have been lodged in the High Court, with victims and grieving relatives seeking damages estimated to be worth up to £100 million.

But in the legal document submitted to the High Court in February, AstraZeneca said: “It is admitted that the AZ vaccine can, in very rare cases, cause TTS. The causal mechanism is not known. 

“Further, TTS can also occur in the absence of the AZ vaccine (or any vaccine). Causation in any individual case will be a matter for expert evidence.”

So after admitting in principle that their vaccine could cause TTS, they still intend to fight each individual case on the basis of specific causation, arguing that it may just be ‘coincidental’ that the victim developed TTS shortly after being injected. But note that AZ’s case rests upon the statement that the causal mechanism is not known. This is a lie. It is known, if not in every specific medical/scientific detail, then at least in outline and, in the case of the adenovirus vector, it has been known for more than 15 years that adenoviruses used in gene therapy can cause blood platelet activation. This means that the company which developed the Oxford-AZ vaccine could have and should have anticipated, in advance, that their product would cause TTS, no matter how rare such occurrences were. Given the hundreds of millions worldwide who were injected with their product, they must have known that significant numbers of people would be very seriously injured and even die. Even in the UK, the number of ‘rare’ cases would be significant.

I wrote about the AZ vaccine way back in May 2021:

It was my second most viewed post ever because Archbishop Carlo Maria Viganò linked to it in a letter he wrote to US bishops warning them about the dangers of the Covid vaccines.

What I said and quoted in that post is relevant to the statements that AZ are making to the court today:

We now have emerging research which might explain why the adenovirus vectored Oxford AZ DNA jab is even more dangerous than the mRNA Pfizer and Moderna jabs. It has to do with the genetically modified chimpanzee adenovirus itself and the way in which it gets its ‘payload’ of SARS-Cov-2 spike encoding DNA into our cells.

During the last months many countries have started the immunization of millions of people by using vector-based vaccines. Unfortunately, severe side effects became overt during these vaccination campaigns: cerebral venous sinus thromboses (CVST), absolutely rare under normal life conditions, were found as a severe side effect that occurred 4-14 days after first vaccinations. Besides CVST, Splanchnic Vein Thrombosis (SVT) was also observed. This type of adverse event has not been observed in the
clinical studies of AstraZeneca, and therefore led immediately to a halt in vaccinations in several European countries. These events were mostly associated with thrombocytopenia, and thus, similar to the well-known Heparin-induced thrombo cytopenia (HIT). Meanwhile, scientists have proposed a mechanism
to explain this vaccine-induced thrombocytopenia. However, they do not provide a satisfactory explanation for the late thromboembolic events. Here, we present data that may explain these severe side effects which have been attributed to adenoviral vaccines.

That was talking about a published study which proposed a mechanism for soluble spike proteins entering the blood and causing thrombosis and thrombocytopenia, which was related to the chosen delivery mechanism involving the adenovirus and the spike coding DNA. AZ might not have anticipated this and the claim is that it did not show up in the clinical trials. But, they would almost certainly have been aware of the following:

That’s all OK then. What they don’t tell you, probably because they didn’t read the study carefully, assuming they even read it at all, is that this newly identified faulty transcription of DNA to RNA, resulting in the production of truncated, soluble spike proteins, is not the only problem with the viral vector ‘vaccines’. The other major problem is the genetically modified adenovirus vector itself. It too can bind to platelets and cause thrombocytopenia. The issue has been known about for at least 15 years, so there’s no excuse for the manufacturers to claim that such an adverse effect was unforeseen – it wasn’t. Here for instance:

Thrombocytopenia has been consistently reported following the administration of adenoviral gene transfer vectors. The mechanism underlying this phenomenon is currently unknown.

And here:

Thrombocytopenia is a major adverse effect of high dose systemic administration of adenoviral (Ad) gene therapy vectors. While a previous report did not find platelet activation by Ad [1], recent studies have shown that Ad may activate platelets [2] and binds in vivo to murine thrombocytes resulting in hepatic sequestration [3]. Ad-induced thrombocytopenia has been shown to be dose-dependent, saturable and reversible [4], compatible with a ligand-receptor mechanism. Recently, binding of Ad to platelet was indirectly suggested following interference of platelet adhesion to fibronectin after incubation with Ad [2]. In this study we developed a direct flow cytometry assay to quantitatively analyze Ad attachment to human platelets in vitro and to characterize their interaction.

What this clearly tells us is that there are two major problems with the AZ viral vector vaccine, giving rise to very similar serious thrombotic adverse reactions associated with a low blood platelet count and those two problems arise separately as a result of SARS-CoV-2 spike proteins migrating into the blood, plus the adenovirus itself binding to blood platelets. The authors of this new study do actually point this out, but then they appear to ignore it, along with the media reporting on the paper.

The UK government is picking up the tab on AZ’s legal fees (i.e. the British taxpayer is paying for them to defend themselves against claims from injured victims and dead victim’s families). That is outrageous. They knew for sure, in advance, before even one person was injected, that the administration of their product would likely result in the injuries and deaths which victims are taking them to court for.